Article citationsMore>>

Chan, J.C.N., Deerochanawong, C., Shera, A.S., Yoon, K.H., Adam, J.M.F., Binh, T.V., Chan, S.P., Fernando, R.E., Horn, L.C., Khue, N.T., Litonjua, A.D., Soegondo, S. and Zimmet, P. (2007) Role of metformin in the initiation of pharmacotherapy for Type 2 diabetes: An AsianPacific perspective. Diabetes Research and Clinical Practice, 75, 255-266. http://dx.doi.org/10.1016/j.diabres.2006. 06.023

has been cited by the following article:

• TITLE: Improved β-cell function rather than increased insulin sensitivity is associated with reduction in hemoglobin A1c in newly diagnosed Type 2 diabetic patients treated with metformin

  AUTHORS: Satoru Sumitani, Shinya Morita, Reiko Deguchi, Koichi Hirai, Kosuke Mukai, Yoshihiko Utsu, Shunji Miki, Bunzo Sato, Hideji Nakamura, Soji Kasayama

  KEYWORDS: Metformin; Type 2 Diabetes; β-Cell Function; Insulin Sensitivity

  JOURNAL NAME: Journal of Diabetes Mellitus, Vol.4 No.1, February 8, 2014

  ABSTRACT: β-cell dysfunction and decreased insulin sensitivity are believed to be two chief mechanisms that participate in deterioration of glycemic control in Type 2 diabetes. Meformin is widely accepted as the first-line oral agent in the treatment of Type 2 diabetes. However, the relative contributions of improved β-cell function and increased insulin sensitivity to reduction in hemoglobin A1c (HbA1c) are unclear in newly diagnosed Type 2 diabetic patients treated with metformin. We investigated β-cell function and insulin sensitivity in relation to reduction in HbA1c in 20 newly diagnosed Type 2 diabetic patients (17 men and 3 women, mean age 49.1 ± 10.1 years, mean body mass index 26.4 ± 5.2 kg/m2) treated with metformin for 16 weeks. We used homeostasis model assessment (HOMA) 2%B and HOMA2%S as estimates of β-cell function and insulin sensitivity, respectively. Median HOMA2%B and HOMA2%S significantly increased from 38.8 to 68.8 (p p = 0.004), respectively. In univariate regression analysis, reduction in HbA1c was highly correlated with change in HOMA2%B (r = -0.866, p r = -0.264, p = 0.260). Furthermore, multivariate regression analysis with reduction in HbA1c as a dependent variable showed that increase in HOMA2%B but not that in HOMA2%S was a significant dependent variable (β = -0.847, p β-cell function rather than increased insulin sensitivity is associated with reduction in HbA1c. These results suggest that metformin reduces HbA1c chiefly through improved β-cell function rather than increased insulin sensitivity in patients with newly diagnosed Type 2 diabetes.